e-learning
resources
Virtual 2020
Pre-Congress Content
Challenges and updates in nursing care around the world
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What influences patient choice of antifibrotic treatment in IPF?
E. Briggs (Birmingham(West Midlands), United Kingdom), G. Burge (Birmingham(West Midlands), United Kingdom), H. Alldrick (Birmingham(West Midlands), United Kingdom), M. Bellamy (Birmingham(West Midlands), United Kingdom), S. Burge (Birmingham(West Midlands), United Kingdom), G. Walters (Birmingham(West Midlands), United Kingdom)
Source:
Virtual Congress 2020 – Challenges and updates in nursing care around the world
Session:
Challenges and updates in nursing care around the world
Session type:
E-poster session
Number:
590
Disease area:
-
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Briggs (Birmingham(West Midlands), United Kingdom), G. Burge (Birmingham(West Midlands), United Kingdom), H. Alldrick (Birmingham(West Midlands), United Kingdom), M. Bellamy (Birmingham(West Midlands), United Kingdom), S. Burge (Birmingham(West Midlands), United Kingdom), G. Walters (Birmingham(West Midlands), United Kingdom). What influences patient choice of antifibrotic treatment in IPF?. 590
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
What patients with IPF can expect concerning symptoms and quality of life during first six months of antifibrotic treatment?
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study.
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Impact of compliance and specialist nurse support on IPF survival in patients commenced on antifibrotic therapy
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Effect of sildenafil add-on to antifibrotic treatment in IPF patients
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients?
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?
Source: Eur Respir J 2004; 24: 1-2
Year: 2004
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy?
Source: Eur Respir J 2001; 18: Suppl. 33, 24s
Year: 2001
New antifibrotic drugs: will interstitial diseases patients still need lung transplantation?
Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs
Year: 2020
Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017
Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 57 (3) 2004645; 10.1183/13993003.04645-2020
Year: 2021
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept